Head-to-head evidence
efsubaglutide alfa vs semaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
efsubaglutide alfa
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT06732960 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but each dose cohort was small, with approximately 10 participants per cohort and a 8:2 active-to-placebo allocation. Because the registry provides no primary endpoint results, it is not possible to determine whether the weight-loss comparison was met.
Next expected readout: November 2026 · NCT07163650 (registry estimate)
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: October 2026 · NCT07505303 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efsubaglutide alfa's landscape · semaglutide's landscape